3 Top Dividend Stocks to Buy Right Now — With Dividend Yields Above 5%
These companies sport recent dividend yields of 5.1%, 5.6%, and 6.6%.
Mindfully Curated
These companies sport recent dividend yields of 5.1%, 5.6%, and 6.6%.
Ark Invest is lightening its stake in three popular investments.
Everyone is celebrating Broadcom’s win, but it benefits Apple, too.
Bloom Energy stock has surged on data center power demand. Could FuelCell be the next big winner?
The cessation of a ceasefire between the U.S. and Iran has far-reaching consequences.
Technology and AI stocks are stealing most of the market’s attention, but these three “boring” stocks offer outperformance potential.
Before you buy for less than $20, there are a few things to consider.
Goldman Sachs is poised for a strong Q2.
Micron stock has been cratering since the company reported earnings in late June.
It’s time to check some key tasks off your list.
Researchers solved the mystery of how soft lithium dendrites crack the hard ceramic inside solid-state batteries, triggering short circuits. The breakthrough could help engineers build safer, longer-lasting batteries for smartphones, electric vehicles,…
Tesla’s revenue towers over Rivian’s, but one company shows steadier growth while the other fluctuates.
Warren Buffett isn’t only worried about the stock market.
These AI stocks sell for low valuations relative to their growth rates.
Coke’s stock price just crossed an important level that coincided with its last stock split 14 years ago.
GE Vernova and Vistra are top-tier bets on the massive AI power boom, but their business models are making all the difference to shareholder returns.
A next-generation pesticide designed to kill crop pests may also be interfering with the reproductive health of bumblebees. Researchers discovered that low-dose exposure to sulfoxaflor changed gene activity, especially in tissues involved in reproducti…
The “SaaS-pocalypse” came for Salesforce, even amid solid earnings numbers and a massive share repurchase.
An accelerated approval for Agios’ key drug to treat sickle cell disease appears to be on the cards.
This exchange-traded fund would definitely benefit from an interest rate hike.